Switch theme
Sign up to access all valuation multiples
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
2013
246
LTM Revenue $25.6M
LTM EBITDA -$208M
-$45.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Editas Medicine has a last 12-month revenue (LTM) of $25.6M and a last 12-month EBITDA of -$208M.
In the most recent fiscal year, Editas Medicine achieved revenue of $32.3M and an EBITDA of -$233M.
Editas Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Editas Medicine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $25.6M | XXX | $32.3M | XXX | XXX | XXX |
| Gross Profit | $25.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$208M | XXX | -$233M | XXX | XXX | XXX |
| EBITDA Margin | -815% | XXX | -721% | XXX | XXX | XXX |
| EBIT | -$214M | XXX | -$239M | XXX | XXX | XXX |
| EBIT Margin | -838% | XXX | -739% | XXX | XXX | XXX |
| Net Profit | -$203M | XXX | -$237M | XXX | XXX | XXX |
| Net Margin | -794% | XXX | -734% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Editas Medicine's stock price is $2.
Editas Medicine has current market cap of $144M, and EV of -$45.4M.
See Editas Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$45.4M | $144M | XXX | XXX | XXX | XXX | $-2.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Editas Medicine has market cap of $144M and EV of -$45.4M.
Editas Medicine's trades at -1.4x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Editas Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Editas Medicine has a P/E ratio of -0.7x.
See valuation multiples for Editas Medicine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $144M | XXX | $144M | XXX | XXX | XXX |
| EV (current) | -$45.4M | XXX | -$45.4M | XXX | XXX | XXX |
| EV/Revenue | -1.8x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | -1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEditas Medicine's last 12 month revenue growth is -40%
Editas Medicine's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Editas Medicine's rule of 40 is -249% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Editas Medicine's rule of X is -915% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Editas Medicine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -815% | XXX | -721% | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | -249% | XXX | -761% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -915% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 617% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 839% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Editas Medicine acquired XXX companies to date.
Last acquisition by Editas Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Editas Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Editas Medicine founded? | Editas Medicine was founded in 2013. |
| Where is Editas Medicine headquartered? | Editas Medicine is headquartered in United States of America. |
| How many employees does Editas Medicine have? | As of today, Editas Medicine has 246 employees. |
| Who is the CEO of Editas Medicine? | Editas Medicine's CEO is Dr. Gilmore O’Neill, M.B.. |
| Is Editas Medicine publicy listed? | Yes, Editas Medicine is a public company listed on NAS. |
| What is the stock symbol of Editas Medicine? | Editas Medicine trades under EDIT ticker. |
| When did Editas Medicine go public? | Editas Medicine went public in 2016. |
| Who are competitors of Editas Medicine? | Similar companies to Editas Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Editas Medicine? | Editas Medicine's current market cap is $144M |
| What is the current revenue of Editas Medicine? | Editas Medicine's last 12 months revenue is $25.6M. |
| What is the current revenue growth of Editas Medicine? | Editas Medicine revenue growth (NTM/LTM) is -40%. |
| What is the current EV/Revenue multiple of Editas Medicine? | Current revenue multiple of Editas Medicine is -1.8x. |
| Is Editas Medicine profitable? | Yes, Editas Medicine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Editas Medicine? | Editas Medicine's last 12 months EBITDA is -$208M. |
| What is Editas Medicine's EBITDA margin? | Editas Medicine's last 12 months EBITDA margin is -815%. |
| What is the current EV/EBITDA multiple of Editas Medicine? | Current EBITDA multiple of Editas Medicine is 0.2x. |
| What is the current FCF of Editas Medicine? | Editas Medicine's last 12 months FCF is -$175M. |
| What is Editas Medicine's FCF margin? | Editas Medicine's last 12 months FCF margin is -686%. |
| What is the current EV/FCF multiple of Editas Medicine? | Current FCF multiple of Editas Medicine is 0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
